Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291291045> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W4291291045 endingPage "S159" @default.
- W4291291045 startingPage "S158" @default.
- W4291291045 abstract "The aim of this study is to develop an LC-MS/MS method that can be used to identify the in vitro metabolites of bucinnazine. The method validation was evaluated according to the ASB Standards for Method Validation in Forensic Toxicology. A calibration model, bias calculations, precision calculations, a carryover study, and calculation of the limit of detection and limit of quantitation were evaluated for method validation. Bucinnazine hydrochloride was incubated at 37 °C with Sprague-Dawley rat microsomes (Gibco, New York, USA) for up to three hours for metabolite formation. Analyses were carried out using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). For identification of the metabolites, LC-MS/MS analysis was performed on a Shimadzu LC-MS/MS 8050 system (Shimadzu Corp., Kyoto, Japan) equipped with a Poroshell HPH C18 column with a gradient mobile phase consisting of 5 mM ammonium formate and 0.1% formic acid in water as mobile phase A, and 100% methanol as mobile phase B. Fentanyl-d5 was used as the internal standard. The ion transitions for bucinnazine and fentanyl-d5 were 273 m/z -> 117 m/z and 273 m/z -> 91 m/z, and 342 m/z -> 105 m/z and 342 m/z - > 188 m/z, respectively. Method validation was successfully performed, allowing the method to be used for sample analysis. Metabolite formation was observed over a time period of 0 minutes, 30 minutes, 90 minutes, and 180 minutes. Metabolites were identified by observing increasing and decreasing peaks in the chromatograms of the samples. Peaks observed in both the samples and the controls were excluded from the analysis. Given the increase in illicit bucinnazine cases in the United States, a deeper understanding of its metabolites as biomarkers is important for the development of reliable identification strategies to detect bucinnazine misuse cases. At least two metabolites of bucinnazine were identified using LC-MS/MS. Hydroxylation and dealkylation of the parent compound was observed, and an initial metabolic pathway of bucinnazine was described. Further work to identify other metabolites, and to identify the specific enzymes responsible for metabolite formation will be completed." @default.
- W4291291045 created "2022-08-14" @default.
- W4291291045 creator A5037708033 @default.
- W4291291045 creator A5089821568 @default.
- W4291291045 date "2022-09-01" @default.
- W4291291045 modified "2023-10-05" @default.
- W4291291045 title "In vitro metabolic profile of the new synthetic opioid bucinnazine by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)" @default.
- W4291291045 doi "https://doi.org/10.1016/j.toxac.2022.06.270" @default.
- W4291291045 hasPublicationYear "2022" @default.
- W4291291045 type Work @default.
- W4291291045 citedByCount "0" @default.
- W4291291045 crossrefType "journal-article" @default.
- W4291291045 hasAuthorship W4291291045A5037708033 @default.
- W4291291045 hasAuthorship W4291291045A5089821568 @default.
- W4291291045 hasBestOaLocation W42912910451 @default.
- W4291291045 hasConcept C119128265 @default.
- W4291291045 hasConcept C162356407 @default.
- W4291291045 hasConcept C185592680 @default.
- W4291291045 hasConcept C2775986502 @default.
- W4291291045 hasConcept C2777379063 @default.
- W4291291045 hasConcept C2777477808 @default.
- W4291291045 hasConcept C31827203 @default.
- W4291291045 hasConcept C43617362 @default.
- W4291291045 hasConcept C55493867 @default.
- W4291291045 hasConcept C64489805 @default.
- W4291291045 hasConcept C71043704 @default.
- W4291291045 hasConceptScore W4291291045C119128265 @default.
- W4291291045 hasConceptScore W4291291045C162356407 @default.
- W4291291045 hasConceptScore W4291291045C185592680 @default.
- W4291291045 hasConceptScore W4291291045C2775986502 @default.
- W4291291045 hasConceptScore W4291291045C2777379063 @default.
- W4291291045 hasConceptScore W4291291045C2777477808 @default.
- W4291291045 hasConceptScore W4291291045C31827203 @default.
- W4291291045 hasConceptScore W4291291045C43617362 @default.
- W4291291045 hasConceptScore W4291291045C55493867 @default.
- W4291291045 hasConceptScore W4291291045C64489805 @default.
- W4291291045 hasConceptScore W4291291045C71043704 @default.
- W4291291045 hasIssue "3" @default.
- W4291291045 hasLocation W42912910451 @default.
- W4291291045 hasOpenAccess W4291291045 @default.
- W4291291045 hasPrimaryLocation W42912910451 @default.
- W4291291045 hasRelatedWork W1992561179 @default.
- W4291291045 hasRelatedWork W2001353325 @default.
- W4291291045 hasRelatedWork W2092328469 @default.
- W4291291045 hasRelatedWork W2158180677 @default.
- W4291291045 hasRelatedWork W2229858648 @default.
- W4291291045 hasRelatedWork W2351302509 @default.
- W4291291045 hasRelatedWork W2392271453 @default.
- W4291291045 hasRelatedWork W28056001 @default.
- W4291291045 hasRelatedWork W2979742567 @default.
- W4291291045 hasRelatedWork W4322758456 @default.
- W4291291045 hasVolume "34" @default.
- W4291291045 isParatext "false" @default.
- W4291291045 isRetracted "false" @default.
- W4291291045 workType "article" @default.